Moleculin Biotech (MBRX) Non-Current Deffered Revenue (2016 - 2018)

Moleculin Biotech's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $107000.0 for Q4 2018.

• In Q4 2018, Non-Current Deffered Revenue changed N/A year-over-year to $107000.0; the TTM figure through Dec 2018 stood at $107000.0 (changed N/A YoY), while the FY2018 annual figure was $107000.0, changed N/A from the prior year.
• Non-Current Deffered Revenue for Q4 2018 stood at $107000.0, down from $150000.0 in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $150000.0 in Q2 2017, with the low at $12500.0 in Q2 2016.
• The 3-year median for Non-Current Deffered Revenue is $125000.0 (2017), against an average of $111785.7.
• The sharpest annual moves came in 2017 and 2018: Non-Current Deffered Revenue surged 1100.0% in 2017, then gained 20.0% in 2018.
• Moleculin Biotech's Non-Current Deffered Revenue stood at $88000.0 in 2016, then surged by 70.45% to $150000.0 in 2017, then retreated by 28.67% to $107000.0 in 2018.
• Business Quant data shows MBRX's Non-Current Deffered Revenue at $107000.0 in Q4 2018, $150000.0 in Q1 2018, and $150000.0 in Q3 2017.